Angiocare S.R.L.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Angiocare S.R.L. in Cluj Napoca, the Cardiology team is running studies focused on cardiovascular diseases, especially forms of heart failure and difficult-to-control hypertension. The research is aimed at evaluating new treatment approaches and understanding how they may improve outcomes for people with serious heart conditions.
- Studies in chronic heart failure and heart failure with reduced ejection fraction
- Research on uncontrolled and resistant hypertension to assess better blood pressure control
- Trials testing whether new therapies can reduce cardiovascular death, heart failure hospitalizations, and urgent care visits
- Evaluation of treatments intended to improve symptoms, safety, and overall heart function
These trials reflect a strong focus on improving care for patients living with complex cardiovascular conditions, with an emphasis on practical treatment benefit and long-term risk reduction.
Nutritional and Metabolic Diseases
The site also contributes to research in nutritional and metabolic diseases, with studies centered on severe hypertriglyceridemia and related lipid disorders. This work explores whether new therapies can lower elevated blood fats and support better metabolic health.
- Investigation of severe hypertriglyceridemia to measure reductions in fasting triglyceride levels
- Research on metabolic risk factors that may contribute to broader cardiovascular disease
- Testing novel treatment options designed to improve lipid control and reduce future health risks
- Clinical evaluation of therapies aimed at helping patients with persistent abnormal lipid levels
Overall, the metabolic research at Angiocare S.R.L. complements its heart-focused program by addressing lipid-related conditions that can influence long-term cardiovascular health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Angiocare S.R.L.
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 2 | Unknown | 2024-10-18 | 2025-08-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.